In this issue:
Atezolizumab + chemotherapy: promising in extensive-stage SCLC
Brigatinib vs crizotinib in ALK-positive NSCLC
CT lung cancer screening in high-risk asymptomatic patients
Durvalumab improves OS in NSCLC
Using PD-(L)1 therapy in patients on baseline steroids
Use TMB as a biomarker in NSCLC?
18F-FDG PET for monitoring therapeutic efficacy of PD-(L)1 therapy
Web-based nomograms predict site-specific cancer recurrence
Capmatinib + gefitinib in EGFR-mutated, MET-dysregulated NSCLC
Please login below to download this issue (PDF)